GlassScriptPhysician profile
Rajshekar Narasimaiah
NPI 1457367088
$6,633.71
in general payments reported to CMS, 2019-2025
39 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $626 · 2021: $793 · 2022: $1,195 · 2023: $825 · 2024: $1,393 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.80 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $864.20 | 2019-2025 | Ingrezza |
| Abbvie INC. | $687.87 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $495.93 | 2019-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $426.51 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $411.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $386.70 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $355.74 | 2020-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.34 | 2023-2025 | Jardiance |
| Lundbeck LLC | $280.80 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $242.71 | 2022-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $222.51 | 2020-2024 | |
| Lilly USA, LLC | $194.09 | 2022-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $189.72 | 2024-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $174.05 | 2021-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Exact Sciences Corporation | $125.40 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $115.28 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $110.24 | 2022-2025 | Breztri |
| Mylan Specialty L.P. | $101.34 | 2019-2022 | |
| Axsome Therapeutics, INC. | $99.89 | 2022-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.66 | 2020-2025 | Caplyta |
| Pfizer INC. | $87.61 | 2020-2025 | |
| Vivus LLC | $78.61 | 2024 | Qsymia |
| Sunovion Pharmaceuticals INC. | $73.74 | 2021-2022 | |
| Amarin Pharma, INC. | $67.03 | 2020 | |
| Allergan, INC. | $56.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.84 | 2024-2025 | Invega Sustenna, Spravato |
| Glaxosmithkline, LLC. | $45.46 | 2025 | Shingrix |
| E.R. Squibb & Sons, L.L.C. | $44.81 | 2020-2025 | Cobenfy |
| Phathom Pharmaceuticals, INC. | $31.49 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $31.21 | 2023-2024 | |
| Ardelyx, INC. | $29.29 | 2025 | Ibsrela |
| Tactile Systems Technology INC | $25.64 | 2025 | Flexitouch Plus, Nimbl |
| Abbott Laboratories | $18.89 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $17.94 | 2021 | |
| Neuronetics, INC. | $17.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.06 | 2021 | |
| Vertos Medical, INC. | $15.88 | 2024 | Mild Device Kit |
| Irhythm Technologies, INC. | $14.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Vistapharm, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajshekar Narasimaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.